Medical technology firm Ventric Health has agreed to a partnership with pharmacy services provider Stellus Rx to connect outpatient heart failure detection with pharmacist-led medication management.
The initiative’s main focus is on moving patients directly from initial diagnosis to four-pillar guideline-directed medical therapy (GDMT) within primary care practices.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ventric stated that clinicians will use Vivio, a US Food and Drug Administration (FDA)-cleared diagnostic system that assesses left ventricular end-diastolic pressure in under five minutes.
The point-of-care tool combines cardiac pressure and volume waveform analysis with the digital Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to detect Stage B and Stage C heart failure. The test functions without imaging, specialist appointments, or invasive procedures.
When tests show elevated pressure or early-stage disease, clinics can refer patients to virtual clinical pharmacists at Stellus Rx.
These pharmacists embed directly into practices’ electronic health record (EHR) systems to coordinate with doctors, track vitals, and adjust drug doses biweekly.
Their responsibilities also include managing prior authorisations, reducing financial obstacles, and dispensing medications directly to patients’ homes with optional compliance packaging.
Ventric, CMO, Thomas Cheek commented: “Identifying heart failure early at the point of care is a critical first step, but the true value of diagnosis is only realised when it leads immediately to optimised, guideline-directed treatment.
“By collaborating with Stellus Rx, we are giving primary care providers a complete solution, enabling them to detect elevated left ventricular end-diastolic pressure in minutes and quickly transition patients into a proven care management programme that drives long-term adherence and protects patient health.”
Primary care providers face operational obstacles when initiating four-pillar GDMT, which includes angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Optimising doses demands frequent laboratory monitoring, regular adjustments, insurance paperwork, and extensive patient counselling.
Without dedicated management support, individuals with pre-existing conditions such as chronic kidney disease, hypertension, or type 2 diabetes often receive inadequate doses, increasing the risk of hospitalisations and emergency department visits.
The joint care pathway serves health systems, Medicare Accountable Care Organizations (ACOs), and Medicare Advantage plans.
Ventric Health is based in Pasadena, California, while Stellus Rx delivers remote clinical pharmacy services across the US.
